FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC: 45% ORR in Advanced Patients

Executive Brief

News Report

The News: FDA approves datopotamab deruxtecan for EGFR-mutated NSCLC.
Clinical Win: 45% overall response rate in advanced NSCLC patients.
Target Specialty: Oncology

Key Data at a Glance

Overall Response Rate: 45%
Duration of Response: 6.5 months
Recommended Dosage: 6 mg/kg every 3 weeks

On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This approval is significant as it addresses a critical need for effective treatment options in a patient population with limited responses to existing therapies.

Clinical Context

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. Among NSCLC patients, those with EGFR mutations represent a distinct subgroup that often responds to targeted therapies such as EGFR tyrosine kinase inhibitors (TKIs). However, resistance to these therapies frequently develops, leading to disease progression. Current treatment options for patients with EGFR-mutated NSCLC who have progressed after previous therapies are limited, highlighting the need for new therapeutic strategies. Datopotamab deruxtecan is an antibody-drug conjugate designed to target and deliver cytotoxic agents directly to cancer cells, potentially improving outcomes in this challenging population.

Key Findings

The FDA approved datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC based on data showing a confirmed overall response rate (ORR) of 45% in patients who had received prior treatment with an EGFR-directed therapy and platinum-based chemotherapy (95% CI: 35, 54) [9].

The approval was based on pooled data from two clinical trials: TROPION-Lung05 and TROPION-Lung01, which included a total of 114 patients with locally advanced or metastatic EGFR-mutated NSCLC [9].

The median duration of response (DOR) was reported as 6.5 months (95% CI: 4.2, 8.4) [9].

Safety & Tolerability

The recommended dosage for datopotamab deruxtecan-dlnk is 6 mg/kg administered as an intravenous infusion once every three weeks until disease progression or unacceptable toxicity occurs [9].
Clinicians should consult current prescribing information for full dosing guidance.

What This Means for Clinical Practice

Datopotamab deruxtecan provides a new treatment option for patients with EGFR-mutated NSCLC who have progressed after standard therapies, including EGFR TKIs and platinum-based chemotherapy. The 45% ORR indicates that nearly half of treated patients may experience a meaningful response, which is critical in a population with limited options. Clinicians should consider incorporating datopotamab deruxtecan into treatment plans for eligible patients, particularly those who have exhausted other therapies. Ongoing monitoring for adverse effects, including interstitial lung disease and ocular reactions, will be essential to ensure patient safety and optimize outcomes.

The approval of datopotamab deruxtecan reflects the evolving landscape of targeted therapies in NSCLC, emphasizing the importance of personalized treatment approaches. As more data emerges from ongoing studies, the role of datopotamab deruxtecan in combination with other therapies will need to be explored further, raising questions about its potential in earlier lines of treatment and in combination strategies.

Clinical Perspective

Workflow: Clinicians should assess eligibility for datopotamab deruxtecan in patients with advanced EGFR-mutated NSCLC who have failed prior therapies.

Economics: The introduction of datopotamab deruxtecan may impact treatment costs and resource allocation in oncology settings.

Patient Outcomes: Improved response rates may lead to better patient outcomes and quality of life for those with limited treatment options.

Dr. Rahul Verma, Oncology

References

FDA — FDA grants accelerated approval to datopotamab deruxtecan-dlnk

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC: 45% ORR in Advanced Patients

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Related Articles

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer Screening

USPSTF Updates BRCA Testing Guidelines: Who to Screen for Breast and Ovarian Cancer

Zilovertamab Vedotin Shows Promising Results in CLL: 40% ORR in Phase II Trial

Verified HCP Portal